Nanobiotix disclosed its share capital and voting rights structure as of July 31, 2026, reporting 50,833,462 shares outstanding.

The late-stage clinical biotechnology company filed the disclosure in accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers).

Share Capital and Voting Rights

The filing details the breakdown between theoretical and exercisable voting rights for shareholders.

Theoretical voting rights serve as the basis for calculating threshold crossings under Article 223-11 of the AMF General Regulations. This figure includes all shares with attached voting rights, even those with suspended rights.

Exercisable voting rights represent the net count available at shareholders’ meetings. This calculation excludes shares held in treasury by the company where voting rights are suspended.

About Nanobiotix

Nanobiotix is headquartered in Paris and listed on Euronext Paris and Nasdaq Global Select Market. The company focuses on physics-based therapeutic approaches across oncology, bioavailability, and central nervous system disorders.

Nanobiotix, a late-stage clinical biotechnology company listed on Euronext Paris and Nasdaq, disclosed its share capital and voting rights structure as of June 30, 2026. The filing, issued on July 30, 2026, from Paris, France, provides transparency on shareholder equity distribution in compliance with articles L.233-8 II of the French Commercial Code and article 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers). This disclosure ensures investors have accurate data regarding control thresholds and exercisable voting power within the company.

The regulatory submission details the distinction between theoretical and exercisable voting rights, a standard requirement for companies listed on French exchanges. Theoretical voting rights serve as the basis for calculating threshold crossings under Article 223-11 of the AMF General Regulations. This calculation includes all shares attached to voting rights, even those where voting rights are suspended. In contrast, exercisable voting rights exclude shares held in treasury by the company, providing a clearer picture of votes available at shareholders’ meetings.

Share Capital and Voting Rights Data

As of June 30, 2026, Nanobiotix reported specific figures for its outstanding shares and associated voting power. The data reflects the company’s capitalization status following its listings on Euronext Paris since 2012 and the Nasdaq Global Select Market in New York City since December 2020.

The difference between theoretical and exercisable voting rights is minimal, indicating that very few shares are currently suspended or held in treasury without voting capacity. This alignment suggests a stable shareholder base with consistent voting power across the company’s equity instruments.

Corporate Background and Regulatory Context

Nanobiotix is headquartered in Paris, France, with a subsidiary in Cambridge, Massachusetts. Incorporated in 2003, the company focuses on physics-based therapeutic approaches for oncology, bioavailability, and central nervous system disorders. It owns more than 30 patent families associated with three nanotechnology platforms.

The disclosure aligns with ongoing regulatory obligations for dual-listed entities. By publishing these figures, Nanobiotix maintains compliance with both French market authorities and international investor expectations. The ISIN code for the company’s shares is FR0011341205, with ticker symbols NBTX on Nasdaq and NANO on Euronext Paris.

What the Numbers Show

The near-parity between theoretical (54,486,890) and exercisable (54,464,772) voting rights highlights a highly liquid and active shareholder register. The small variance of 22,118 rights likely represents shares temporarily suspended or held in treasury, which do not impact immediate voting outcomes significantly. For analysts monitoring ownership concentration, this data confirms that no substantial blocks of voting power are dormant or restricted, ensuring that shareholder decisions reflect the broad consensus of the equity base.